Microcirculation, Dialysis Modality, and Sequestered Salt in Dialysis Patients
Official title: The Microcirculation, Dialysis Modality and Sequestered Salt
Run by Amsterdam UMC, location VUmc · NCT06327750 · Data updated 2026-11-12
This study tests five dialysis approaches (different modes and dialysate sodium levels) to see how they affect tiny blood vessel function and hidden salt in adult dialysis patients.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 23 (estimated) |
| Sponsor | Amsterdam UMC, location VUmc Academic / other |
| Locations | 2 sites (Amstelveen, North Holland and 1 other locations) |
| Status | Recruiting |
| Started | June 2, 2026 |
| Main results expected | May 2028 |
| Study ends | May 2028 |
| Registry record updated | September 11, 2026 |
| Trial ID | NCT06327750 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with end-stage kidney disease on HD or HDF, treated at least 3 months, meeting specific sodium, urea clearance, and flow criteria.
✕Probably not a fit
Patients with very limited life expectancy or contraindications to MRI/related imaging may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The trial compares five treatment strategies combining hemodialysis or hemodiafiltration with specific dialysate sodium levels to measure changes in microcirculation and sequestered sodium content over four weeks. It aims to clarify whether high-volume HDF improves vascular function and salt handling more than standard HD or other configurations. The study uses a predefined set of inclusion and exclusion criteria to enroll adult patients on HD or HDF for at least three months. Outcomes focus on microcirculatory parameters and SSC in a real-world clinical setting.
Why it matters
Potential benefit: If successful, patients may experience better microvascular health and more accurate sodium management, potentially influencing survival and quality of life.
How similar studies have gone: Previous research suggests microcirculation and salt handling are linked to dialysis outcomes, but this exact modality/sodium-level comparison is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years * Treatment with HD or HDF 3 x per week during at least 4 hours for at least 3 months * Blood flow rate feasiblity of ≥350 ml/min * Residual diuresis \<200 ml/day * Plasma Na before dialysis 137-145 mmol/L at baseline * spKt/Vurea ≥ 1.2 * Ability to understand study procedures and willingness to provide informed consent Exclusion Criteria: * Severe incompliance to dialysis procedure and accompanying prescriptions, especially frequency and duration of dialysis treatment * Life expectancy \< 3 months due to non-renal disease * Expected transplantation within 6 months * Access recirculation \> 10% * Participation in another clinical intervention trial * Metal implants (e.g. implantable cardioverter defibrillators) * Severe obesity (MRI Ø 60 cm ≈ abdominal circumference ≤ 188 cm) * Claustrophobia
Where it's running
-
Niercentrum aan de Amstel (Elyseklinieken)
Amstelveen, North Holland, Netherlands Recruiting -
Dianet Amsterdam
Amsterdam, North Holland, Netherlands Recruiting
Study contacts
- Principal investigator: Muriel PC Grooteman, MD PhD — Amsterdam UMC
- Study coordinator: Muriel PC Grooteman, MD PhD
- Email: mpc.grooteman@amsterdamumc.nl
- Phone: +3120 566 5990
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ribupatide PK in People with Kidney Impairment
This study tests how a single shot of ribupatide behaves in the body for people with severe kidney problems compared to those with normal kidney function.
-
Intradiay dialysis exercise to improve posture in adults with end-stage kidney disease
This study tests whether a 12-week supervised exercise program done during dialysis can improve posture in adults on maintenance hemodialysis.
-
Pumpkin seed oil for people on hemodialysis
This study tests whether taking pumpkin seed oil daily for 3 months helps reduce inflammation and improve-related lab markers in people with end-stage kidney disease on dialysis.
-
Porcine thymokidney transplant for end-stage renal disease
This study tests whether a GalKO porcine thymokidney transplant can keep kidney function without dialysis in adults with end-stage kidney disease who are unlikely to get a standard donor kidney soon.
-
How inflammatory diseases change the way your body handles medicines.
This study will see if inflammatory conditions like type 2 diabetes, IBD, or end-stage kidney disease change how common medicines are processed and increase the chance of side effects.
-
CRISPR-edited donor kidney transplant to reduce rejection risk
This trial will see if donor kidneys edited with CRISPR to turn off key HLA genes can lower rejection in adults with end-stage kidney disease receiving transplants.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.